215 related articles for article (PubMed ID: 29654831)
1. Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells.
Allam RM; Al-Abd AM; Khedr A; Sharaf OA; Nofal SM; Khalifa AE; Mosli HA; Abdel-Naim AB
Toxicol Lett; 2018 Jul; 291():77-85. PubMed ID: 29654831
[TBL] [Abstract][Full Text] [Related]
2. Estrogenic phenol and catechol metabolites of PCBs modulate catechol-O-methyltransferase expression via the estrogen receptor: potential contribution to cancer risk.
Ho PW; Garner CE; Ho JW; Leung KC; Chu AC; Kwok KH; Kung MH; Burka LT; Ramsden DB; Ho SL
Curr Drug Metab; 2008 May; 9(4):304-9. PubMed ID: 18473748
[TBL] [Abstract][Full Text] [Related]
3. Leptin influences estrogen metabolism and accelerates prostate cell proliferation.
Habib CN; Al-Abd AM; Tolba MF; Khalifa AE; Khedr A; Mosli HA; Abdel-Naim AB
Life Sci; 2015 Jan; 121():10-5. PubMed ID: 25433128
[TBL] [Abstract][Full Text] [Related]
4. Modulatory Effects of Fingolimod (FTY720) on the Expression of Sphingolipid Metabolism-Related Genes in an Animal Model of Alzheimer's Disease.
Jęśko H; Wencel PL; Lukiw WJ; Strosznajder RP
Mol Neurobiol; 2019 Jan; 56(1):174-185. PubMed ID: 29687345
[TBL] [Abstract][Full Text] [Related]
5. Estradiol 17β and its metabolites stimulate cell proliferation and antagonize ascorbic acid-suppressed cell proliferation in human ovarian cancer cells.
Li HH; Zhao YJ; Li Y; Dai CF; Jobe SO; Yang XS; Li XF; Patankar MS; Magness RR; Zheng J
Reprod Sci; 2014 Jan; 21(1):102-11. PubMed ID: 23757313
[TBL] [Abstract][Full Text] [Related]
6. The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers.
Tolba MF; Omar HA; Hersi F; Nunes ACF; Noreddin AM
Mol Cell Endocrinol; 2019 May; 488():79-88. PubMed ID: 30904591
[TBL] [Abstract][Full Text] [Related]
7. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
Pchejetski D; Bohler T; Brizuela L; Sauer L; Doumerc N; Golzio M; Salunkhe V; Teissié J; Malavaud B; Waxman J; Cuvillier O
Cancer Res; 2010 Nov; 70(21):8651-61. PubMed ID: 20959468
[TBL] [Abstract][Full Text] [Related]
8. ERα phenotype, estrogen level, and benzo[a]pyrene exposure modulate tumor growth and metabolism of lung adenocarcinoma cells.
Lin S; Lin CJ; Hsieh DP; Li LA
Lung Cancer; 2012 Mar; 75(3):285-92. PubMed ID: 21920623
[TBL] [Abstract][Full Text] [Related]
9. FTY720/fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts.
Newton J; Hait NC; Maceyka M; Colaco A; Maczis M; Wassif CA; Cougnoux A; Porter FD; Milstien S; Platt N; Platt FM; Spiegel S
FASEB J; 2017 Apr; 31(4):1719-1730. PubMed ID: 28082351
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.
Carruba G
J Cell Biochem; 2007 Nov; 102(4):899-911. PubMed ID: 17786930
[TBL] [Abstract][Full Text] [Related]
11. FTY720 (Fingolimod) attenuates basal and sphingosine-1-phosphate-evoked thyroid cancer cell invasion.
Kalhori V; Magnusson M; Asghar MY; Pulli I; Törnquist K
Endocr Relat Cancer; 2016 May; 23(5):457-68. PubMed ID: 26935838
[TBL] [Abstract][Full Text] [Related]
12. Sphingolipid profile alters in retinal dystrophic P23H-1 rats and systemic FTY720 can delay retinal degeneration.
Stiles M; Qi H; Sun E; Tan J; Porter H; Allegood J; Chalfant CE; Yasumura D; Matthes MT; LaVail MM; Mandal NA
J Lipid Res; 2016 May; 57(5):818-31. PubMed ID: 26947037
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Biological Evaluation of FTY720 (Fingolimod) Derivatives with Aromatic Head Group as Anticancer Agents.
Lee T; Moon HS; Kim SW; Shrestha J; Shin SM; Lee JY; Kim S; Park EY; Baek DJ
Chem Pharm Bull (Tokyo); 2018; 66(10):1015-1018. PubMed ID: 30270236
[TBL] [Abstract][Full Text] [Related]
14. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
15. Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens.
Zhu YS; Cai LQ; Huang Y; Fish J; Wang L; Zhang ZK; Imperato-McGinley JL
J Androl; 2005; 26(4):500-8; discussion 509-10. PubMed ID: 15955889
[TBL] [Abstract][Full Text] [Related]
16. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.
Chua CW; Lee DT; Ling MT; Zhou C; Man K; Ho J; Chan FL; Wang X; Wong YC
Int J Cancer; 2005 Dec; 117(6):1039-48. PubMed ID: 15986440
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of vemurafenib and fingolimod (FTY720) in vemurafenib‑resistant melanoma cell lines.
Takahashi T; Abe N; Kanoh H; Banno Y; Seishima M
Mol Med Rep; 2018 Dec; 18(6):5151-5158. PubMed ID: 30320355
[TBL] [Abstract][Full Text] [Related]
18. The estrogen receptor signaling pathway activated by phthalates is linked with transforming growth factor-β in the progression of LNCaP prostate cancer models.
Lee HR; Hwang KA; Choi KC
Int J Oncol; 2014 Aug; 45(2):595-602. PubMed ID: 24858230
[TBL] [Abstract][Full Text] [Related]
19. 2-Methoxyestradiol, an endogenous 17β-estradiol metabolite, inhibits microglial proliferation and activation via an estrogen receptor-independent mechanism.
Schaufelberger SA; Rosselli M; Barchiesi F; Gillespie DG; Jackson EK; Dubey RK
Am J Physiol Endocrinol Metab; 2016 Mar; 310(5):E313-22. PubMed ID: 26732685
[TBL] [Abstract][Full Text] [Related]
20. In vitro model of mammary estrogen metabolism: structural and kinetic differences between catechol estrogens 2- and 4-hydroxyestradiol.
Dawling S; Hachey DL; Roodi N; Parl FF
Chem Res Toxicol; 2004 Sep; 17(9):1258-64. PubMed ID: 15377160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
